Hoba Therapeutics raises EUR 23 million in a Series A to advance new drug candidate against chronic neuropathic pain

COPENHAGEN, Denmark, Dec. 11, 2023 /PRNewswire/ — Hoba Therapeutics, a Novo Holdings-founded Danish biotech company dedicated to developing novel therapeutic proteins for patients living with chronic neuropathic pain and hearing loss, today announced that it has raised EUR 23 million…